In a brief filed with a federal appeals court, the Department of Justice (DOJ) has asserted that the whistleblower provisions of the False Claims Act are not unconstitutional and that the off-label marketing of a drug cannot by itself form the basis for a finding that federal health care program reimbursements for the drug violated the statute (United States ex rel. Penelow v.... Read More